PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yet they didn't mind updating us end of 2023 with incomplete data when they had already presented incomplete data in September or October 2023, because they needed money. Once they got it, they decided to poop on the people who provided and just talk to everyone else. A small company I know, but it is not too complex to throw investors a bone, is it?
Sorry that should be 2024.
Oops
The company cannot conjure up results from partial incomplete data. It is also unfortunate that both of our trials have conspired to reach important data points around the same time. Third / fourth quarter 2025.
That’s just down to enrolment, selection, planned dosing, medical scans and data analysis. Even then they cannot report on individual cases so enough data has to be verified before it can be compiled and released in an RNS.
By reading the various RNS’s about how the trails are progressing it is sensible not to expect the trial reports until we are beyond the first half of 2024.
However, there is always the possibility that the company could announce news on a deal at any time.
Waiting is frustrating but it will be worth it if the data continues on the positive upward trajectory as previously reported.
When are they gonna present some results to shareholders…
Https://www.ejcancer.com/article/S0959-8049(24)00776-7/abstract
Not sure if these results could be directly compared to SCIB1. Perhaps, a good read for technical people.
Bad news for the patients and Merck, but positive for Scancell.
- scib1 / iscib1+ have virtually no side-effects so puts them at the head of the pack for avoiding these issues with combo's
- Merck could now on the lookout for a replacement.
Https://www.clinicaltrialsarena.com/news/merck-melanoma-regimen-trial/#:~:text=Merck%20cancels%20trial%20of%20melanoma,in%20the%20trial's%20coformulation%20arm.&text=The%20trial's%20vibostolimab%20and%20pembrolizumab,defined%20futility%20criteria%20for%20RFS.
Drug halted.
Virginia Maxwell
Senior Associate Producer, Conferences at Cambridge Healthtech Institute
Posted this in linked in . Mentions thought-provoking presentations and “Scancell Ltd”
Senior Associate Producer, Conferences at Cambridge Healthtech Institute
Cambridge Healthtech Institute’s 12th Annual Immuno-Oncology Summit will take place at the Hilton Philadelphia at Penn’s Landing, August 7-9. We are looking forward to thought-provoking presentations and panel discussions on innovations and advances in Therapeutic Cancer Vaccines including the following participants on August 7-8: Moderna, Scancell Ltd, VBI Vaccines Inc., Geneos Therapeutics, Elicio Therapeutics, Imvax, Inc., and Evaxion Biotech A/S. The cancer vaccine track is followed by Tumor Microenvironment, August 8-9, with informative presentations by Genentech, Kineta, Vaccinex, Macomics, Ankyra Therapeutics, Deka Biosciences, Inc, and Incendia Therapeutics. Please visit https://lnkd.in/eC-rXvRj to view additional talks and networking opportunities covering the 3 days of the event. We hope you can join us in Philadelphia this summer! #cancer #vaccine #tumor #microenvironment #IOSummit
Hi Bermuda
Thanks. Notwithstanding Ray P's reply, I would endeavour to ask any question on recruiting, however general or specific that you care to feed to me. In addition to questions in open session, I have managed to exploit LD's willingness after the last three AGMs to answer additional questions one-on-one after formalities ended.
I would be happy to write up and post any responses that don't go to camera/recording.
Kind regards. Almas
We will get to view the event on Proactive's YouTube channel once posted
https://www.proactiveinvestors.co.uk/events
"Watch the event afterwards on our YouTube channel"
Almas,
Thanks for that.
If nothing else it would be good to at least get a clear picture on how recruitment is going across the board but particularly for Modi1 - which cohorts are still recruiting and how many recruited so far. If you have the time I'd be interested to hear any feedback or comments from you on the presentation and I'm sure others would appreciate it too. No problems though if it's not possible.
Hi Bermuda.
Thanks.
The Proactive presentation on Wednesday, 29th May is to be given by Lindy herself.
Bookings are open; places were still available when I made mine last week.
It will be around six months since the last update by then, so I am obviously hopeful (I wish I could write "confident") that Prof Durrant will not be re-presenting that information on the 29th...
Almas
From a few weeks back on Macmillan:
“ I also assumed that because my treatment was now a combination trial; modi-1 plus nivo, that I couldn’t stop the nivo and continue with the modi. This was confirmed.
My last discussion with S, he thought the modi vaccines were complete (after 9 months) and just nivo remained. But when I had a different view, he looked it up and confirmed they continued. Therefore, I concluded they didn’t know the optimum timeframe for the modi either. To be fair, it’s a phase 1 trial so that is not the objective. On this basis the initial trial timeframe was for fewer injections, and I’d had them all, it was logical to conclude I’d had the benefit from these as well. Oncologist nodded.”
…..would have continued with Modi-1 on its own but figured that the benefit had been obtained.
Looks like Scancell are doing another Proactive One2One event on 29th May. It'll be interesting to see who is presenting.
https://www.proactiveinvestors.co.uk/register/event_details/444
Can't read the full article? What does it say?
But if you also can only read the same vague headline I can, then your interpretation of it RE Genmabs specific relationship with Scancell is more than a bit of a stretch. IMO.
Https://www.ft.com/content/2f3caeee-ff64-47eb-b00e-6568ad1f1858
Hope they're still interested in more from Scancell.. but it looks like they have headed to China to find more innovation.
That's Inanaco on the other side. The research and time put Into the Information he produces and shares Is mind blowing. I don't understand most of It myself. With all the positive large positive %ages produced In the SCLP Trials you have to wonder why the Co hasn't been bought out
Sarah Danson also referenced this in her recent presentation at the Melanoma patient conference
https://www.google.com/search?client=safari&sca_esv=73778d81cd87c189&hl=en-gb&sxsrf=ADLYWIL6OsT1cntPtbrbd-fE_2cdETt6lQ:1715672278957&q=sarah+danson&tbm=vid&source=lnms&prmd=invmbtz&sa=X&ved=2ahUKEwiX0POl0YyGAxVrVEEAHRazCR0Q0pQJegQICBAB&biw=393&bih=656&dpr=3#
Not really directly related, but some interesting sidebar comments in this article, suggesting that Scancell and others in this field may be on to something bigger re targeting the immune system…..
Richard Scolyer: Top doctor remains brain cancer-free after a year https://www.bbc.co.uk/news/world-australia-69006713
Bojo,
I think the real excitement may come with the checkpoint inhibitor patients, if you look at things like Keytruda, it’s Ph1 trial wasn’t amazing but good enough to allow continuation of the trials. Larger cohorts then demonstrated clinical application and utility.
The fact modi is showing activity is good but I think the later cohorts will help demonstration further it’s clinical application.
Thanks Berm, that’s helpful to not take my inferences out of context. Both therefore also highlights that moditope is seen by both sides of the immune system which so good, especially if both can be harnessed.
burble,
regarding your cd8+ /cd4+ t cell comment. scancell published some research back in september showing they had identified a cd8+ t cell response to some ****citrullinated peptides:-
'there is ample evidence suggesting an important role of cd8 t cells in eradicating tumor cells. here we present data for a novel class of antigens recognized in the tumor microenvironment by cd8 t cells. our previous studies have demonstrated that ptm specific cd4 t-cell responses provide survival benefits against aggressive tumor models in mice and suggest the presentation of modified epitopes in the tumor environment. in this study, we have shown the first evidence of cd8-mediated responses to hcit peptides and demonstrated that these are capable of selectively recognizing the modified but not the wt epitopes.'
https://jitc.bmj.com/content/11/10/e006966
Hi Burble,
Appreciate you taking the time to share your thoughts which have helped me focus on relevant points. So early data shows Moditope has demonstrated potential in humans. Not getting carried away but this is encouraging.
The bit that attracted my attention re poster 1 was a bit that was cut off the end of your copy, Burble: viz “…..complete regression of 70% of established tumours”
Also, no copy or comment re the 3rd poster on SCIB1? Or is there nothing new there?